Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Risperidone drug monitoring - A useful clinical tool?
Autore:
Odou, P; Levron, JC; Luyckx, M; Brunet, C; Robert, H;
Indirizzi:
EPSM Lille Metropole, Serv Pharm, F-59241 Armentieres, France EPSM Lille Metropole Armentieres France F-59241 9241 Armentieres, France Fac Sci Pharmaceut & Biol, Lab Biopharm & Pharm Clin, Lille, France Fac Sci Pharmaceut & Biol Lille France harm & Pharm Clin, Lille, France Janssen Res Fdn, Val De Reuil, France Janssen Res Fdn Val De Reuil France nssen Res Fdn, Val De Reuil, France Fac Sci Pharmaceut & Biol, Lab Pharm Clin Pharmacocinet & Pharmacol, Lille, France Fac Sci Pharmaceut & Biol Lille France cinet & Pharmacol, Lille, France
Titolo Testata:
CLINICAL DRUG INVESTIGATION
fascicolo: 4, volume: 19, anno: 2000,
pagine: 283 - 292
SICI:
1173-2563(200004)19:4<283:RDM-AU>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
PERFORMANCE LIQUID-CHROMATOGRAPHY; CYTOCHROME-P450 3A; SCHIZOPHRENIC-PATIENTS; PLASMA-CONCENTRATIONS; RADIORECEPTOR ASSAY; CLOZAPINE; HALOPERIDOL; METABOLISM; 9-HYDROXYRISPERIDONE; PHARMACOKINETICS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Odou, P EPSM Lille Metropole, Serv Pharm, Rue Gen Leclerc,BP 199, F-59241 Armentieres, France EPSM Lille Metropole Rue Gen Leclerc,BP 199 Armentieres France F-59241
Citazione:
P. Odou et al., "Risperidone drug monitoring - A useful clinical tool?", CLIN DRUG I, 19(4), 2000, pp. 283-292

Abstract

Background: Risperidone is an atypical antipsychotic drug that has been marketed in France since 1996. Therapeutic failures have been observed with risperidone. Objective: To investigate whether interactions with the cytochrome P450 (CYP) isoenzymes implicated in risperidone metabolism could explain these treatment failures. Design and Setting: This was a retrospective study of clinical and drug monitoring data from 50 patients treated by five psychiatrists in northern France. Methods: The concentration of active drug (risperidone + 9-hydroxy risperidone) in serum was evaluated by high performance liquid chromatographyand radio receptor assay. Clinical efficacy was assessed by the global improve ment (CGI(2)) item of the Clinical Global Impression rating scale. Results: Statistical analysis revealed a significant increase in efficacy when the serum concentration of active drug was between 25 and 150 mu g/L compared with when it was out of this range. Carbamazepine, a CYP3A4 inducer, dramatically decreased the concentration of the active moiety of risperidone; on the contrary, CYP3A4 inhibitors (alprazolam and valproic acid) increased the concentration of active drug. The metabolism of risperidone by CYP3A4 did not lead to the formation of metabolite(s) with anti-D-2 dopaminergic activity. Drugs interacting with CYP2D6 altered the risperidone/9-hydroxy-risperidone ratio but did not change the total amount of active drug. Conclusions: We have established a therapeutic range for risperidone. CYP3A4 is a major pathway for risperidone metabolism. Consideration of these factors in clinical practice should lead to improved outcomes for patients treated with risperidone.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 19:06:37